title: Therapeutic opportunities for muscarinic receptors in the central nervous system.
authors.affiliation: Eli Lilly Research Laboratories, Indianapolis, Indiana 46285, USA. felder@lilly.com
authors.forename: C C
authors.initials: CC
authors.lastname: Felder
authors.forename: F P
authors.initials: FP
authors.lastname: Bymaster
authors.forename: J
authors.initials: J
authors.lastname: Ward
authors.forename: N
authors.initials: N
authors.lastname: DeLapp
mesh_terms: D000494:Allosteric Regulation; D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D001921:Brain / Q000502:physiology*; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D018721:Muscarinic Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D018727:Muscarinic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy*; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000235:genetics / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy*; D015398:Signal Transduction
chemical_list: D002800:Cholinesterase Inhibitors; D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D011976:Receptors, Muscarinic